Post-polio syndrome: Clinical manifestations and cerebrospinal fluid markers

Future Neurology

Volumn 2, Issue 4, 2007, Pages 451-463

  Fiorini, Michele ^a   Zanusso, Gianluigi ^a   Baj, Andreina ^b   Bertolasi, Laura ^a   Toniolo, Antonio ^b   Monaco, Salvatore ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

14 3 3 proteins; Antivirals; Cystatin C; Cytokines; Enteroviruses; Fatigue; Intravenous immunoglobulin; Picornaviruses; Post polio syndrome; Virus persistence

Indexed keywords

ANTIVIRUS AGENT; BIOCHEMICAL MARKER; CREATINE KINASE; CYSTATIN C; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; ORAL POLIOMYELITIS VACCINE; PROTEIN 14 3 3; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AXONAL INJURY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ELECTROMYOGRAPHY; FATIGUE; FLACCID PARALYSIS; FUNCTIONAL DISEASE; HUMAN; IMMUNOBLOTTING; IMMUNOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MOTOR UNIT POTENTIAL; MUSCLE STRENGTH; MUSCLE WEAKNESS; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; POSTPOLIOMYELITIS SYNDROME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T LYMPHOCYTE ACTIVATION; VIRUS GENOME;

EID: 34447345110     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.4.451     Document Type: Review

References (86)

1. Kincaid O, Lipton HL: Viral myelitis: an update. Curr. Neurol. Neurosci. Rep. 6, 469-474 (2006).
2. Gawne AC, Halstead LS: Post-polio syndrome: historical perspective, epidemiology and clinical presentation. Neurorehabilitation 8, 73-81 (1997).
3. Sunnerhagen KS, Grimby G: Muscular effects in late polio. Acta Physiol. Scand. 171, 335-340 (2001).
4. Kew O, Morris-Glasgow V, Landaverde M et al.: Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296, 356-359 (2002).
5. Oppenheim H: Ueber die poliomyelitis anterior chronica. Arch. Psychiatr. Nervenkr. 19, 225-226 (1888).
6. Halstead LS, Rossi CD: New problems in old polio patients: results of a survey of 539 polio survivors. Orthopedics 8, 845-850 (1985).
7. Cosgrove JL, Alexander MA, Kitts EL, Swan BE, Klein MJ, Bauer RE: Late effects of poliomyelitis. Arch. Phys. Med. Rehabil. 68, 4-7 (1987).
8. Ragonese P, Fierro B, Salemi G et al.: Prevalence and risk factors of post-polio syndrome in a cohort of polio survivors. J. Neurol. Sci. 236, 31-35 (2005).
9. Ramlow J, Alexander M, LaPorte R, Kaufmann C, Kuller L: Epidemiology of the post-polio syndrome. Am. J. Epidemiol. 136, 769-786 (1992).
10. Trojan DA, Cashman NR: Post-poliomyelitis syndrome. Muscle Nerve 31, 6-19 (2005).
11. Mulder DW, Rosenbaum RA, Layton DD Jr: Late progression of poliomyelitis or forme fruste amyotrophic lateral sclerosis? Mayo Clin. Proc. 47, 756-761 (1972).
12. Halstead LS: Assessment and differential diagnosis for post-polio syndrome. Orthopedics 14, 1209-1217 (1991).
13. Farbu E, Gilhus NE, Barnes MP et al.: EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur. J. Neurol. 13, 795-801 (2006).
14. Windebank AJ, Litchy WJ, Daube JR, Kurland LT, Codd MB, Iverson R: Late effects of paralytic poliomyelitis in Olmsted County, Minnesota. Neurology 41, 501-507 (1991).
15. Windebank AJ, Daube JR, Litchy WJ et al.: Late sequelae of paralytic poliomyelitis in Olmsted County, Minnesota. Birth Defects Orig. Artic. Ser. 23, 27-38 (1987).
16. Lonnberg F: Late onset polio sequelae in Denmark. Results of a nationwide survey of 3,607 polio survivors. Scand. J. Rehabil. Med. Suppl. 28, 1-32 (1993).
17. Ivanyi B, Nollet F, Redekop WK et al.: Late onset polio sequelae: disabilities and handicaps in a population-based cohort of the 1956 poliomyelitis outbreak in the Netherlands. Arch. Phys. Med. Rehabil. 80, 687-690 (1999).
18. Nollet F, Ivanyi B, Beelen A, De Haan RJ, Lankhorst GJ, De Visser M: Perceived health in a population based sample of victims of the 1956 polio epidemic in the Netherlands. J. Neurol. Neurosurg. Psychiatry. 73, 695-700 (2002).
19. Halstead LS, Gawne AC, Pham BT: National rehabilitation hospital limb classification for exercise, research, and clinical trials in post-polio patients. Ann. NY Acad. Sci. 753, 343-353 (1995).
20. Agre JC, Rodriquez AA, Franke TM, Swiggum ER, Harmon RL, Curt JT: Low-intensity, alternate-day exercise improves muscle performance without apparent adverse effect in postpolio patients. Am. J. Phys. Med. Rehabil. 75, 50-58 (1996).
21. Kidd D, Howard RS, Williams AJ, Heatley FW, Panayiotopoulos CP, Spencer GT: Late functional deterioration following paralytic poliomyelitis. QJM 90, 189-196 (1997).
22. Wekre LL, Stanghelle JK, Lobben B, Oyhaugen S: The Norwegian Polio Study 1994: a nation-wide survey of problems in long-standing poliomyelitis. Spinal Cord 36, 280-284 (1998).
23. Ivanyi B, Nollet F, Redekop WK et al.: Late onset polio sequelae: disabilities and handicaps in a population-based cohort of the 1956 poliomyelitis outbreak in The Netherlands. Arch. Phys. Med. Rehabil. 80, 687-690 (1999).
24. Jubelt B, Agre JC: Characteristics and management of postpolio syndrome. JAMA 284, 412-414 (2000).
25. Rekand T, Albrektsen G, Langeland N, Aarli JA: Risk of symptoms related to late effects of poliomyelitis. Acta Neurol. Scand. 101, 153-158 (2000).
26. Chang CW, Huang SF: Varied clinical patterns, physical activities, muscle enzymes, electromyographic and histologic findings in patients with post-polio syndrome in Taiwan. Spinal Cord 39, 526-531 (2001).
27. Farbu E, Rekand T, Gilhus NE: Post-polio syndrome and total health status in a prospective hospital study. Eur. J. Neurol. 10, 407-413 (2003).
28. Halstead LS: Late Effects of Poliomyelitis. Halstead LS, Wiechers DO (Eds). Symposia Foundation, FL, USA, 121-134 (1985).
29. Jubelt B, Drucker J: Poliomyelitis and the post-polio syndrome. In: Motor Disorders. Younger DS (Ed.). Lippincott Williams & Wilkins, PA, USA 381-395 (1999).
30. Klingman J, Chui H, Corgiat M, Perry J: Functional recovery. A major risk factor for the development of postpoliomyelitis muscular atrophy. Arch. Neurol. 5, 645-647 (1988).
31. Wiechers DO, Hubbell SL: Late changes in the motor unit after acute poliomyelitis. Muscle Nerve 4, 524-528 (1981).
32. Wiechers DO: New concepts of the reinnervated motor unit revealed by vaccine-associated poliomyelitis. Muscle Nerve 11, 356-364 (1988).
33. Halstead LS, Rossi D: Post-polio syndrome. Birth Defects 23, 13-26 (1987).
34. Owen RR: Post-polio syndrome and cardiopulmonary conditioning. West. J. Med. 154, 557-558 (1991).
35. Owen RR, Jones D: Polio residual clinic: conditioning exercise program. Orthopedics 8, 882-883 (1985).
36. Dean E, Ross J: Effect of modified aerobic training on movement energetics in polio survivors. Orthopedics 14, 1243-1246 (1991).
37. Ernstoff B, Wetterqvist H, Kvist H, Grimby G: Endurance training effect on individuals with postpoliomyelitis. Arch. Phys. Med. Rehabil. 77, 843-848 (1996).
38. Bruno RL, Galski T, De Luca J: The neuropsychology of post-polio fatigue. Arch. Phys. Med. Rehabil. 74, 1061-1065 (1993).
39. Gandevia SC, Allen GM, Neering IR, Middleton J, Jones R: Strength, voluntary drive, and endurance during isometric contractions in prior polio subjects. Ann. NY Acad. Sci. 753, 408-409 (1995).
40. Allen GM, Gandevia SC, Neering IR, Hickie I, Jones R, Middleton J: Muscle performance, voluntary activation and perceived effort in normal subjects and patients with prior poliomyelitis. Brain 117, 661-670 (1994).
41. Bruno RL, Cohen JM, Galski T, Frick NM: The neuroanatomy of post-polio fatigue. Arch. Phys. Med. Rehabil. 75, 498-504 (1994).
42. Chaudhuri A, Behan PO: Fatigue in neurological disorders. Lancet 363, 978-988 (2004).
43. Thomas CK, Zijdewind I: Fatigue of muscles weakened by death of motoneurons. Muscle Nerve 33, 21-41 (2006).
44. Bruno RL, Sapolsky R, Zimmerman JR, Frick NM: Pathophysiology of a central cause of post-polio fatigue. Ann. NY Acad. Sci. 753, 257-275 (1995).
45. Bruno RL: Abnormal movements in sleep as a post-polio sequelae. Am. J. Phys. Med. Rehabil. 77, 339-343 (1998).
46. Appenzeller O: Autonomic neuropathies. In: Neuropathies (Volume 51). Handboook of Clinical Neurology. Vinken I, Matthews PJ (Eds). Elsevier Science Publisher B.V. Amsterdam, Holland 475-490 (1987).
47. Klingman J, Chui H, Corgiat M, Perry J, Stalberg EV, Sonoo M: Assessment of variability in the shape of the motor unit action potential, the 'jiggle,' at consecutive discharges. Muscle Nerve 17, 1135-1344 (1994).
48. Sandberg A, Hansson B, Stalberg E: Comparison between concentric needle EMG and macro EMG in patients with a history of polio. Clin. Neurophysiol. 110, 1900-1908 (1999).
49. Pezeshkpour GH, Dalakas MC: Long-term changes in the spinal cords of patients with old poliomyelitis. Signs of continuous disease activity. Arch. Neurol. 45, 505-508 (1988).
50. Miller MC: Post-polio syndrome spinal cord pathology. Case report with immunopathology. Ann. NY Acad. Sci. 753, 186-193 (1995).
51. Fishman PS: Late-convalescent poliomyelitis. Corticospinal tract integrity. Arch. Neurol. 44, 98-100 (1987).
52. Medana I, Martinic MA, Wekerle H, Neumann H: Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 159, 809-815 (2001).
53. Dalakas MC: Morphologic changes in the muscles of patients with postpoliomyelitis neuromuscular symptoms. Neurology 38, 99-104 (1988).
54. Dalakas MC: Elevated creatine kinase level in post-polio syndrome. JAMA 268, 3248 (1992).
55. Dalakas MC: Neuromuscular symptoms in patients with old poliomyelitis. Eur. Neurol. 25, 381-387 (1986).
56. Ginsberg AH, Gale MJ Jr, Rose LM, Clark EA: T-cell alterations in late postpoliomyelitis. Arch. Neurol. 46, 497-501 (1989).
57. Illa I, Leon-Monzon M, Agboatwalla M, Ilyas A, Latov N, Dalakas MC: Antiganglioside antibodies in patients with acute polio and post-polio syndrome. Ann. NY Acad. Sci. 753, 374-377 (1995).
58. Sharief MK, Hentges R, Ciardi M: Intrathecal immune response in patients with the post-polio syndrome. N. Engl. J. Med. 325, 749-755 (1991).
59. Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T: Prior poliomyelitis-evidence of cytokine production in the central nervous system. J. Neurol. Sci. 205, 9-13 (2002).
60. Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA: Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur. J. Neurol. 14, 60-65 (2007).
61. Muir P, Nicholson F, Sharief MK et al.: Evidence for persistent enterovirus infection of the central nervous system in patients with previous paralytic poliomyelitis. Ann. NY Acad. Sci. 753, 219-232 (1995).
62. Leon-Monzon ME, Dalakas MC: Detection of poliovirus antibodies and poliovirus genome in patients with the post-polio syndrome. Ann. NY Acad. Sci. 753, 208-218 (1995).
63. Leparc-Goffart I, Julien J, Fuchs F, Janatova I, Aymard M, Kopecka H: Evidence of presence of poliovirus genomic sequences in cerebrospinal fluid from patients with postpolio syndrome. J. Clin. Microbiol. 34(8), 2023-2026 (1996).
64. Baj A, Monaco S, Zanusso G, Dall'Ora E, Bertolasi L, Toniolo A: Virology of the post-polio syndrome. Future Virol. 2, 183-192 (2007).
65. Melchers W, de Visser M, Jongen P: The postpolio syndrome: no evidence for poliovirus persistence. Ann. Neurol. 32, 728-732 (1992).
66. Berg D, Holzmann C, Riess O: 14-3-3 proteins in the nervous system. Nat. Rev. Neurosci. 4, 752-762 (2003).
67. Liu Y, Yin G, Surapisitchat J et al.: Laminar flow inhibits TNF-induced ASK1 activation by preventing dissociation of ASK1 from its inhibitor 14-3-3. J. Clin. Invest. 107, 917-923 (2001).
68. Satoh J, Kurohara K, Yukitake M, Kuroda Y: The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur. Neurol. 41, 216-225 (1999).
69. Hsich G, Kenney K, Gibbs CJ et al.: The 14-3-3 brain protein in cerebrospinal fluid as a marker for trasmissible spongiform encephalopathies. N. Engl. J. Med. 13, 924-930 (1996).
70. Bonora S, Zanusso G, Raiteri R et al.: Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. Clin. Infect. Dis. 36, 1492-1495 (2003).
71. Martinez-Yelamos A, Saiz A, Sanchez-Valle R et al.: 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 57, 722-724 (2001).
72. De Seze J, Peoc'h K, Ferriby D et al.: 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. J. Neurol. 249, 626-627 (2002).
73. Bartosik-Psujek H, Archelos JJ: Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J. Neurol. 251, 414-420 (2004).
74. Colucci M, Roccatagliata L, Capello E et al.: The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult. Scler. 10, 477-481 (2004).
75. Fiorini M, Zanusso G, Benedetti MD, Righetti PG, Monaco S: Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. Proteomics Clin. Appl. (2007) (In press).
76. Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF: CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56, 1528-1533 (2001).
77. Saiz A, Graus F, Dalmau J, Pifarre A, Marin C, Tolosa E: Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann. Neurol. 46, 774-777 (1999).
78. Bersano A, Fiorini M, Allaria S et al.: Detection of CSF 14-3-3 protein in Guillain-Barre syndrome. Neurology 67(12), 2211-2216 (2006).
79. Zanusso G, Fiorini M, Farinazzo A et al.: Phosphorylated 14-3-3ζ protein in the CSF of neuroleptic-treated patients. Neurology 64, 1618-1620 (2005).
80. Trojan DA, Collet JP, Shapiro S et al.: A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology 53, 1225-1233 (1999).
81. Chan KM, Strohschein FJ, Rydz D, Allidina A, Shuaib A, Westbury CF: Randomized controlled trial of modafinil for the treatment of fatigue in post-polio patients. Muscle Nerve 33, 138-141 (2006).
82. Bruno RL, Zimmerman JR, Creange SJ, Lewis T, Molzen T, Frick NM: Bromocriptine in the treatment of post-polio fatigue: a pilot study with implications for the pathophysiology of fatigue. Am. J. Phys. Med. Rehabil. 75, 340-347 (1996).
83. Stein DP, Dambrosia JM, Dalakas MC: A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann. NY Acad. Sci. 753, 296-302 (1995).
84. Dalakas MC, Aksamit AJ, Madden DL, Sever JL: Administration of recombinant human leukocyte α2-interferon in patients with amyotrophic lateral sclerosis. Arch. Neurol. 43, 933-935 (1986).
85. Dinsmore S, Dambrosia J, Dalakas MC: A double-blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. Ann. NY Acad. Sci. 753, 303-313 (1995).
86. Gonzalez H, Sunnerhagen KS, Sjoberg I, Kaponides G, Olsson T, Borg K: Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol. 5, 493-500 (2006).